Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iterum Therapeutics Plc

1.44
-0.0100-0.69%
Post-market: 1.470.0300+2.08%19:19 EDT
Volume:280.64K
Turnover:405.03K
Market Cap:49.80M
PE:-1.14
High:1.49
Open:1.49
Low:1.42
Close:1.45
Loading ...

Company Profile

Company Name:
Iterum Therapeutics Plc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
9
Office Location:
3 Dublin Landings,North Wall Quay,Dublin,Co. Dublin,Ireland
Zip Code:
D01 C4E0
Fax:
- -
Introduction:
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Directors

Name
Position
Brenton K. Ahrens
Independent Director, Interim Chairman of the Board
Corey N. Fishman
Director, Chief Executive Officer
David G. Kelly
Independent Director
Mark Chin
Independent Director
Patrick J. Heron
Independent Director
Ronald M. Hunt
Independent Director
Shahzad Malik
Independent Director

Shareholders

Name
Position
Corey N. Fishman
Director, Chief Executive Officer
Judith M. Matthews
Chief Financial Officer
Michael W. Dunne
Chief Scientific Officer